Overcoming key challenges in cancer immunotherapy with engineered T cells.
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
entrez:
16
8
2020
pubmed:
17
8
2020
medline:
23
12
2020
Statut:
ppublish
Résumé
A number of clinical trials are currently testing chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered T cells for the treatment of haematologic malignancies and selected solid tumours, and CD19-CAR-T cells have produced impressive clinical responses in B-cell malignancies. Here, we summarize the current state of the field, highlighting the key aspects required for the optimal application of CAR and TCR-engineered T cells for cancer immunotherapy. Toxicities, treatment failure and disease recurrence have been observed at different rates and kinetics. Several strategies have been designed to overcome these hurdles: the identification and combination of known and new antigens, together with the combination of immunotherapeutic and classical approaches may overcome cancer immune evasion. New protocols for genetic modification and T cell culture may improve the overall fitness of cellular products and their resistance to hostile tumour immunomodulatory signals. Finally, the schedules of T cell administration and toxicity management have been adapted to improve the safety of this transformative therapeutic approach. In order to develop effective adoptive T cell treatments for cancer, therapeutic optimization of engineered CAR and TCR T cells is crucial, by simultaneously focusing on intrinsic and extrinsic factors. This review focuses on the innovative approaches designed and tested to overcome the hurdles encountered so far in the clinical practice, with new excitement on novel laboratory insights and ongoing clinical investigations.
Identifiants
pubmed: 32796230
doi: 10.1097/CCO.0000000000000664
pii: 00001622-202009000-00003
doi:
Substances chimiques
Receptors, Antigen, T-Cell
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
398-407Références
Campoli M, Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 2008; 27:5869–5885.
Toffalori C, Zito L, Gambacorta V, et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat Med 2019; 25:603–611.
Zeiser R, Vago L. Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. Blood 2019; 133:1290–1297.
Liu M, Guo F. Recent updates on cancer immunotherapy. Precis Clin Med 2018; 1:65–74.
Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015; 348:69–74.
Nerreter T, Letschert S, Götz R, et al. Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T. Nat Commun 2019; 10:3137.
Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med 2018; 24:20–28.
Ali SA, Shi V, Maric I, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 2016; 128:1688–1700.
Shalabi H, Kraft IL, Wang HW, et al. Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. Haematologica 2018; 103:e215–e218.
O’Rourke DM, Nasrallah MP, Desai A, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med 2017; 9:eaaa0984doi:10.1126/scitranslmed.aaa0984.
doi: 10.1126/scitranslmed.aaa0984
Sotillo E, Barrett DM, Black KL, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 2015; 5:1282–1295.
Ruella M, Xu J, Barrett DM, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med 2018; 24:1499–1503.
Bernt KM, Armstrong SA. Targeting epigenetic programs in MLL-rearranged leukemias. Hematology Am Soc Hematol Educ Program 2011; 2011:354–360.
Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446:758–764.
Han BS, Ji S, Woo S, et al. Regulation of the translation activity of antigen-specific mRNA is responsible for antigen loss and tumor immune escape in a HER2-expressing tumor model. Sci Rep 2019; 9:
Hamieh M, Dobrin A, Cabriolu A, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 2019; 568:112–116.
Han X, Wang Y, Wei J, Han W. Multi-antigen--targeted chimeric antigen receptor T cells for cancer therapy. J Hematol Oncol 2019; 12:128Published 2019 Nov 29. doi:10.1186/s13045-019-0813-7.
doi: 10.1186/s13045-019-0813-7
Shah NN, Maatman T, Hari P, Johnson B. Multi targeted CAR-T cell therapies for B-cell malignancies. Front Oncol 2019; 9:146.
Pan J, Niu Q, Deng B, et al. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia 2019; 33:2854–2866.
Liu D, Zhao J, Song Y. Engineering switchable and programmable universal CARs for CAR T therapy. J Hematol Oncol 2019; 12:69.
Jetani H, Garcia-Cadenas I, Nerreter T, et al. CAR T-cells targeting FLT3 have potent activity against FLT3 - ITD + AML and act synergistically with the FLT3-inhibitor crenolanib. Leukemia 2018; 32:1168–1179.
Pont MJ, Hill T, Cole GO, et al. G-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood 2019; 134:1585–1597.
Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31:27–36.
Jazirehi AR. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy. Anticancer Drugs 2010; 21:805–813.
Cosenza M, Pozzi S. The therapeutic strategy of HDAC6 inhibitors in lymphoproliferative disease. Int J Mol Sci 2018; 19:2337Published 2018 Aug 9. doi:10.3390/ijms19082337.
doi: 10.3390/ijms19082337
Cosenza M, Civallero M, Marcheselli L, et al. Ricolinostat, a selective HDAC6 inhibitor, shows antilymphoma cell activity alone and in combination with bendamustine. Apoptosis 2017; 22:827–840.
García-Guerrero E, Götz R, Doose S, et al. Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab. Leukemia 2020; Published online 2020 Apr 29. doi: 10.1038/s41375-020-0840-y.
doi: 10.1038/s41375-020-0840-y
García-Guerrero E, Gogishvili T, Danhof S, et al. Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab. Blood 2017; 129:3386–3388.
Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol 2014; 15:509–524.
Hoffend NC, Magner WJ, Tomasi TB. The epigenetic regulation of dicer and microRNA biogenesis by Panobinostat. Epigenetics 2017; 12:105–112.
Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A 2010; 107:7875–7880.
Schietinger A, Philip M, Krisnawan VE, et al. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity 2016; 45:389–401.
Torres Chavez A, McKenna MK, Canestrari E, et al. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity. J Immunother Cancer 2019; 7:330.
Alizadeh D, Wong RA, Yang X, et al. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol Res 2019; 7:759–772.
Cieri N, Camisa B, Cocchiarella F, et al. Plenary paper IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 2013; 121:573–84.
Zhou J, Jin L, Wang F, et al. Chimeric antigen receptor T (CAR-T) cells expanded with IL-7/IL-15 mediate superior antitumor effects. Protein Cell 2019; 10:764–769.
Mestermann K, Giavridis T, Weber J, et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Sci Transl Med 2019; 11:eaau5907.
Weber EW, Lynn RC, Sotillo E, et al. Pharmacologic control of CAR-T cell function using dasatinib. Blood Adv 2019; 3:711–717.
Feucht J, Sun J, Eyquem J, et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat Med 2019; 25:82–88.
Hinrichs CS, Borman ZA, Cassard L, et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A 2009; 106:17469–17474.
Sommermeyer D, Hudecek M, Kosasih PL, et al. Chimeric antigen receptor-modified T cells derived from defined CD8 + and CD4 + subsets confer superior antitumor reactivity in vivo. Leukemia 2016; 30:492–500.
Gattinoni L, Speiser DE, Lichterfeld M, Bonini C. T memory stem cells in health and disease. Nat Med 2017; 23:18–27.
Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 2017; 543:113–117.
Noviello M, Manfredi F, Ruggiero E, et al. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nat Commun 2019; 10:1065.
Ren J, Liu X, Fang C, et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res 2017; 23:2255–2266.
Rupp LJ, Schumann K, Roybal KT, et al. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep 2017; 7:737.
Choi BD, Yu X, Castano AP, et al. CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. J Immunother Cancer 2019; 7:304.
Wei J, Luo C, Wang Y, et al. PD-1 silencing impairs the antitumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity. J Immunother Cancer 2019; 7:1–15.
Stadtmauer EA, Fraietta JA, Davis MM, et al. CRISPR-engineered T cells in patients with refractory cancer. Science 2020; 367: eaba7365. doi:10.1126/science.aba7365.
doi: 10.1126/science.aba7365
Sachdeva M, Busser BW, Temburni S, et al. Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality. Nat Commun 2019; 10:
Kunert A, Chmielewski M, Wijers R, et al. Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is nontoxic and counteracts immune evasion of solid tumors. Oncoimmunology 2017; 7:e1378842.
Stüber T, Monjezi R, Wallstabe L, et al. Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-- specific-CAR-T-- cells-against-triple--negative breast cancer. J Immunother Cancer 2020; 8:676.
Tang N, Cheng C, Zhang X, et al. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight 2020; 5:e133977Published 2020 Feb 27. doi:10.1172/jci.insight.133977.
doi: 10.1172/jci.insight.133977
Lynn RC, Weber EW, Sotillo E, et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 2019; 576:293–300.
Kato D, Yaguchi T, Iwata T, et al. GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 ab. Elife 2020; 9: e49392. Published 2020 Mar 31. doi:10.7554/eLife.49392.
doi: 10.7554/eLife.49392
Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest 2016; 126:3130–3144.
Cao Y, Lu W, Sun R, et al. Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed/refractory B-cell nonhodgkin lymphoma. Front Oncol 2019; 9: 767. Published 2019 Aug 19. doi:10.3389/fonc.2019.00767.
doi: 10.3389/fonc.2019.00767
Maude SL, Hucks GE, Seif AE, et al. The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL). J Clin Oncol 2017; 35:103–1103.
Linot C, Saini J, Adusumilli PS. Sustained, cell-intrinsic versus intermittent, cell-extrinsic checkpoint blockade in solid tumor CAR T-cell therapy. J Clin Oncol 2020; 38:16–116.
Kuramitsu S, Ohno M, Ohka F, et al. Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses. Cancer Gene Ther 2015; 22:487–495.
Wang X, Walter M, Urak R, et al. Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma. Clin Cancer Res 2018; 24:106–119.
Works M, Soni N, Hauskins C, et al. Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide affiliations: corresponding author. Mol Cancer Ther 2019; 18:2246–2257.
Weber EW, Maus MV, Mackall CL. The emerging landscape of immune cell therapies. Cell 2020; 181:46–62.
Yossef R, Tran E, Deniger DC, et al. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy. JCI Insight 2018; 3:e122467published online. doi:10.1172/jci.insight.122467.
doi: 10.1172/jci.insight.122467
Klebanoff CA, Wolchok JD. Shared cancer neoantigens: making private matters public. J Exp Med 2018; 215:5–7.
Chheda ZS, Kohanbash G, Okada K, et al. Novel and shared neoantigen derived from histone 3 variant H3.3K27 M mutation for glioma T cell therapy. J Exp Med 2018; 215:141–157.
Lo W, Parkhurst M, Robbins PF, et al. Immunologic recognition of a shared p53 mutated neoantigen in a patient with metastatic colorectal cancer. Cancer Immunol Res 2019; 7:534–543.
Zamora AE, Crawford JC, Allen EK, et al. Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8+ T cell responses. Sci Transl Med 2019.
MacKay M, Afshinnekoo E, Rub J, et al. The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat Biotechnol 2020; 38:233–244.
Srivastava S, Salter AI, Liggitt D, et al. Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell 2019; 35:489–503.e8.
Hughes-Parry HE, Cross RS, Jenkins MR. The evolving protein engineering in the design of chimeric antigen receptor T cells. Int J Mol Sci 2020; 21:204Published online 2019 Dec 27. doi: 10.3390/ijms21010204.
doi: 10.3390/ijms21010204
Majzner RG, Rietberg SP, Sotillo E, et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov 2020; 10:702–723.
Gee MH, Han A, Lofgren SM, et al. Antigen identification for orphan T cell receptors expressed on tumor-infiltrating lymphocytes. Cell 2018; 172:549–563.e16.
Thomas S, Mohammed F, Reijmers RM, et al. Framework engineering to produce dominant T cell receptors with enhanced antigen-specific function. Nat Commun 2019; 4451 (Article number), published online 2019 Oct 01.
Sharma P, Harris DT, Stone JD, Kranz DM. T-cell receptors engineered de novo for peptide specificity can mediate optimal t-cell activity without self cross-reactivity. Cancer Immunol Res 2019; 7:2025–2035.
Crowther MD, Dolton G, Legut M, et al. Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1. Nat Immunol 2020; 21:178–185.
Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 2019; 25:625–638.
Santomasso BD, Park JH, Salloum D, et al. Clinical and biological correlates of neurotoxicity associated with car t-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov 2018; 8:958–971.
Hay KA, Gauthier J, Hirayama AV, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood 2019; 133:1652–1663.
Chou CK, Turtle CJ. Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy. Bone Marrow Transplant 2019; 54:780–784.
Majzner RG, Mackall CL. Clinical lessons learned from the first leg of the CAR T cell journey. Nat Med 2019; 25:1341–1355.
Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 2018; 24:739–748.
Giavridis T, Van Der Stegen SJC, Eyquem J, et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade letter. Nat Med 2018; 24:731–738.
Sterner RM, Sakemura R, Cox MJ, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood 2018; 564:273–277.
Staedtke V, Bai RY, Kim K, et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature 2018; 564:273–277.
Lu Y, Xue J, Deng T, et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory nonsmall-cell lung cancer. Nat Med 2020; 26:732–740.
Brudno JN, Lam N, Vanasse D, et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat Med 2020; 26:270–280.
Ghorashian S, Kramer AM, Onuoha S, et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med 2019; 25:1408–1414.
Xu Y, Yang Z, Horan LH, et al. A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release. Cell Discov 2018; 4:62.
Ying ZT, Long L, Liu H, et al. ET190L1-ARTEMIS T cell therapy to induce complete remission of relapsed and refractory (r/r) B-cell lymphoma with no cytokine release syndrome in the first-in-human clinical study. JCO 2018; 36:15_suppl, 3049–3049.
Leung WH, Gay J, Martin U, et al. Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization. JCI Insight 2019; 5:e124430published online. doi: 10.1172/jci.insight.124430.
doi: 10.1172/jci.insight.124430
Depil S, Duchateau P, Grupp SA, et al. Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov 2020; 19:185–199.
Provasi E, Genovese P, Lombardo A, et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med 2012; 18:807–815.
Philip LPB, Schiffer-Mannioui C, Le Clerre D, et al. Multiplex genome-edited T-cell manufacturing platform for ‘off-the-shelf’ adoptive T-cell immunotherapies. Cancer Res 2015; 75:3853–3864.
Kamiya T, Wong D, Png YT, Campana D. A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells. Blood Adv 2018; 2:517–528.
Yang Y, Kohler ME, Chien CD, et al. TCR engagement negatively affects CD8 but not CD4 CAR T cell expansion and leukemic clearance. Sci Transl Med 2017; 9:eaag1209doi:10.1126/scitranslmed.aag1209.
doi: 10.1126/scitranslmed.aag1209
Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med 2020; 382:545–553.
Klichinsky M, Ruella M, Shestova O, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol 2020; doi: 10.1038/s41587-020-0462-y. [Epub ahead of print].
doi: 10.1038/s41587-020-0462-y.
Themeli M, Kloss CC, Ciriello G, et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol 2013; 31:928–933.
Taylor CJ, Peacock S, Chaudhry AN, et al. Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient hla types. Cell Stem Cell 2012; 11:147–152.
Nianias A, Themeli M. Induced pluripotent stem cell (iPSC)–derived lymphocytes for adoptive cell immunotherapy: recent advances and challenges. Curr Hematol Malig Rep 2019; 14:261–268.